Recently, Fosun Pharma's innovative drug products have received many good news
.
On the evening of August 26, Fosun Pharma announced that its holding subsidiary Fuhong Henlius’ HLX60 (recombinant anti-GARP humanized monoclonal antibody injection) combined with slulimumab injection (Hans-shaped) was used for Advanced/metastatic solid tumor therapy approved for clinical trials in Australia
.
HLX60 is an innovative anti-GARP monoclonal antibody independently developed by the company, which is planned to be used in the treatment of solid tumors and lymphomas
.
The results of preclinical studies have shown that the anti-tumor effect of HLX60 in combination with HLX60 is significantly better than that of HLX60 or HLX60 monotherapy, and the two have a synergistic antitumor effect
.
The application for the Phase 1 clinical trial of HLX60 for the treatment of solid tumors and lymphomas has been accepted by the State Food and Drug Administration in August 2022
.
As of the date of this announcement, there is no similar combination therapy regimen in the world
.
At the same time, the drug registration application for the first-line treatment of locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC) developed by Fuhong Henlius, a subsidiary of Fosun Pharma, was approved.
Accepted by the State Food and Drug Administration
.
This indication is also the fourth indication for Hans-like to be listed in mainland China
.
It is reported that the Hansoid is an innovative anti-PD-1 monoclonal antibody independently developed by Fosun Pharma.
It has been approved by the NMPA in March 2022 for the treatment of unresectable or metastatic microsatellite highly unstable entities that have failed standard therapy.
tumor, and is planned for the treatment of a variety of solid tumors
.
On August 25, Fosun Pharma issued an announcement that its controlling subsidiary, Fosun Kite, received a request from the State Food and Drug Administration to approve the use of Akilence injection (trade name: Yikaida) for the treatment of first-line immunochemotherapy ineffective or in first-line chemotherapy.
Approval for a clinical trial in adult large B-cell lymphoma (r/r LBCL) who relapsed within 12 months after immunochemotherapy
.
This product is a CAR-T cell therapy product Yescarta introduced by the company from Kite Pharma, Inc.
After technology transfer and authorized to be locally produced in China, this product is a cell therapy product
.
As of today, no CAR-T cell therapy product for the treatment of new indications has been approved for marketing in China
.
.
.
.
.
.
.
The success of Fosun Pharma's innovative drugs is the result of the company's continuous strengthening of innovation investment
.
In the first half of this year, Fosun Pharma's R&D investment reached 2.
399 billion yuan, a year-on-year increase of 22.
77%; among which, the research and development expenses were 1.
818 billion yuan, a year-on-year increase of 16.
39%
.
The 2022 semi-annual report shows that in the first half of the year, Fosun Pharma achieved operating income of 21.
34 billion yuan, a year-on-year increase of 25.
88%; net profit was 1.
547 billion yuan, a year-on-year decrease of 37.
67%
.
The decrease in net profit was mainly due to the year-on-year decrease in non-recurring gains and losses caused by losses from changes in fair value
.
The company stated that, thanks to the revenue contribution of new products and anti-epidemic products and the effective control of marketing expenses, the company's operating income and recurring income continued to maintain steady growth
.
Specifically, the launch of new products has injected impetus into the growth of Fosun Pharma
.
In the first half of this year, the proportion of Fosun Pharma’s revenue from new products and second-order new products, including Fubitai (Hong Kong, Macao and Taiwan markets), Hanlikang, Hanquyou, Su Kexin, and Hansizuo, in the company’s pharmaceutical business has exceeded 25%
.
It is also worth mentioning that, as the first CAR-T cell therapy product approved for listing in China, Fosun Kite’s Yikaida (Aquilence Injection), a joint venture of Fosun Pharma, has been on the market until July 2022.
At the end of the month, it has been included in the urban Huimin Insurance and more than 50 commercial insurances in 44 provinces and cities, and nearly 100 treatment centers have been registered
.
